Evaluation of what matters most in existing clinical outcomes assessments in Alzheimer's disease: Neuropsychiatry and behavioral neurology/treatment development and clinical trials. (7th December 2020)

• Record Type: Journal Article
• Authors: Hartry, Ann; Menne, Heather; Wronski, Samantha L.; Paulsen, Russ; Callahan, Leigh F.; Potashman, Michele; Lee, Daniel; Wunderlich, Glen; Hoffman, Deborah; Wieberg, Dan; Kremer, Ian N.; Hauber, Brett; DiBenedetti, Dana B.
• Is Part Of: Alzheimer's & dementia. Volume 16(2020)Supplement 6
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-12-07
• Subjects: Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1002/alz.040100
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Background: The Alzheimer's Disease Patient and Caregiver Engagement (AD PACE) Initiative works to identify and measure treatment‐related needs, preferences, and priorities of individuals with or at risk for Alzheimer's disease (AD) and care partners across the continuum of AD. First, the What Matters Most (WMM) study assessed needs, preferences and priorities of individuals in these populations. The next work will compare the WMM results to concepts in existing clinical outcome assessments (COAs) used in AD trials. This study identifies the most commonly used measures in AD research throughout the disease continuum. Method: Targeted literature and ClinicalTrials.gov searches identified COAs used in AD populations. Studies included pharmacological intervention or registry studies with individuals with preclinical or prodromal AD, mild cognitive impairment (MCI), mild, moderate, or severe AD, or caregivers of these individuals, and at least one type of COA. Results: Over 900 records were retrieved. Records from the literature and Clinicaltrials.gov searches were combined and coded, yielding a total of 109 records for final review. Performance measures were the most common type of COA identified. COAs were most frequently used in MCI, and mild and moderate AD populations; COAs were used less often among prodromal/preclinical and severe AD populations. The six most frequently reported COAs identified were ADAS‐Cog, Mini‐Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI), Alzheimer's Disease Cooperative Study ‐ Activities of Daily living Inventory (ADCS‐ADL), Clinical Dementia Rating Scale (CDR), and Alzheimer's Disease Cooperative Study ‐ Clinical Global Impression of Change (ADCS‐CGIC). Conclusion: Performance measures (e.g., MMSE & CDR) were the most common type of COA identified, followed by clinician‐reported and observational measures. Only three COAs were used in all 5 AD populations: MMSE, ADCS‐ADL, NPI. Very few patient‐reported measures were identified; the most frequently being the EQ5D ( used in 4/5 AD populations). The most commonly used clinician‐reported measures included the NPI, ADCS‐CGIC, and Columbia Suicide Severity Rating Scale (C‐SSRS). The next phase of this work will assess the extent to which these existing measures capture the concepts that are most important to individuals with or at risk for AD and their care partners as identified in the WMM study.